Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

High Risk

Score: 70/100

Failure Rate

50.0%

4 terminated/withdrawn out of 8 trials

Success Rate

42.9%

-43.6% vs industry average

Late-Stage Pipeline

25%

2 trials in Phase 3/4

Results Transparency

167%

5 of 3 completed trials have results

Key Signals

1 recruiting5 with results

Enrollment Performance

Analytics

Phase 2

3(42.9%)

Phase 1

2(28.6%)

Phase 3

2(28.6%)

7Total

Phase 2(3)

Phase 1(2)

Phase 3(2)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (8)

Showing 8 of 8 trials

NCT04973137Phase 3Terminated

A Study to Evaluate the Efficacy and Safety of Birtamimab in Mayo Stage IV Patients With AL Amyloidosis

Role: lead

NCT06699680Phase 1Recruiting

Phase 1 Study of PRX019 in Healthy Adult Volunteers

Role: lead

NCT02312206Phase 3Terminated

The VITAL Amyloidosis Study, a Global Phase 3, Efficacy and Safety Study of NEOD001 in Patients With AL Amyloidosis

Role: lead

NCT02613182Phase 2Terminated

Open-label Extension Study of NEOD001 in Subjects With Light Chain (AL) Amyloidosis

Role: lead

NCT02574676Completed

Quality of Life (QOL) Registry for Patients With AL Amyloidosis

Role: lead

NCT02632786Phase 2Completed

The PRONTO Study, a Global Phase 2b Study of NEOD001 in Previously Treated Subjects With Light Chain (AL) Amyloidosis

Role: lead

NCT03154047Phase 2Terminated

Study in Subjects With Light Chain (AL) Amyloidosis

Role: lead

NCT01707264Phase 1Completed

Phase 1/2, Open Label, Dose Escalation Study of NEOD001 in Subjects With Light Chain (AL) Amyloidosis

Role: lead

All 8 trials loaded